By Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC In the fall of 2019, I wrote a blog called Ode to Patients.  As stresses from many directions have mounted over the past

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC.  If we could quantify the time and money impact of the resources invested in quarterly Board meeting preparation, I wonder if we would

Family Oddball, and a New Class of Safe Oral Autoimmune & Inflammatory Disease Treatment with Blockbuster Potential By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. On day one of the JPM

Just before I chaired a Board meeting last year, I spent a frustratingly painful hour going through many of the uncomfortable details of my divorce process and a set of emotional custody issues with my lawyers. Immediately after hanging up,

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. This blog is dedicated to the front-line healthcare workers, essential service workers, scientists, patients, and their families who confront COVID-19 every day, and

2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. It was truly a horrifically tragic year for humanity, and for America in particular.  As everyone knows,

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC Over the course of my career in healthcare, I’ve been fortunate to serve in a leadership role through four IPOs and even more

By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC. One of the biggest elephants in the room regarding starting and scaling young companies is the tension, often healthy but sometimes detrimental, that exist

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC Prioritization is a concept that we have become intimately aware of, given the continually blurred lines of personal and professional obligations in a

Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine. For those of us in biopharma, it feels like it’s a large and dynamic sector populated by

Part 2: Gaining leverage – and using it wisely By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC. In a recent blog post, I walked through my tips for reading your adversaries’

Part 1: Maintaining your cool – while making your adversary sweat By Deanna Petersen, Chief Business Officer of AVROBIO, as part of the From The Trenches feature of LifeSciVC It’s back-to-school season, and that puts me in the frame of